Zacks Company Profile for Shionogi & Co., Ltd. Unsponsored ADR (SGIOY : OTC) |
|
|
|
Company Description |
Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
Number of Employees: 4,959 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $8.95 |
Daily Weekly Monthly
 |
20 Day Moving Average: 71,257 shares |
Shares Outstanding: 1,701.38 (millions) |
Market Capitalization: $15,227.34 (millions) |
Beta: 0.20 |
52 Week High: $9.14 |
52 Week Low: $6.53 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
0.56% |
-1.21% |
12 Week |
4.43% |
-5.14% |
Year To Date |
28.59% |
16.10% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
1-8 DOSHOMACHI 3-CHOME - OSAKA,M0 541-0045 JPN |
ph: 816-620-2216 fax: - |
None |
http://www.shionogi.com |
|
|
|
General Corporate Information |
Officers
IsaoTeshirogi - President and CEO
Keiichi Ando - Chairperson
Takuko Sawada - Director and Vice Chairperson of the Board
Hiroshi Ozaki - Director
Fumi Takatsuki - Director
|
|
Peer Information
Shionogi & Co., Ltd. Unsponsored ADR (GSAC)
Shionogi & Co., Ltd. Unsponsored ADR (CASI)
Shionogi & Co., Ltd. Unsponsored ADR (ALCD.)
Shionogi & Co., Ltd. Unsponsored ADR (OMNN)
Shionogi & Co., Ltd. Unsponsored ADR (CGPI.)
Shionogi & Co., Ltd. Unsponsored ADR (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 824667109
SIC: 8880
|
|
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 10/27/25
|
|
Share - Related Items
Shares Outstanding: 1,701.38
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.20
Market Capitalization: $15,227.34 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 1.71% |
Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.15 |
Current Fiscal Year EPS Consensus Estimate: $0.73 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: 6.05% |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 10/27/25 |
|
|
|
|